Skip to main content
Premium Trial:

Request an Annual Quote

Myriad's Investment in RainDance Totals $5M

NEW YORK (GenomeWeb News) – Myriad Genetics' investment into RainDance Technologies totals $5.0 million, the Salt Lake City-based company said in its Form 10-Q filed with the US Securities and Exchange Commission this week.

RainDance announced last week the closing of a $20 million Series E financing round, saying Myriad had joined as a strategic equity investor. In its SEC document, Myriad said that it acquired about 28 million shares of RainDance's Series E preferred stock as part of its investment.

It added that the "Series E shares represent less than 5 percent of the total shares outstanding of RainDance's capital stock."

Earlier last month, Myriad and RainDance also announced a multiyear deal for the adoption of RainDance's microdroplet PCR-based target enrichment technology.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.